BIDU

Prezzo Baidu

Closed
BIDU
$125,68
-$0,96(-0,75%)

*Data last updated: 2026-05-04 07:21 (UTC+8)

As of 2026-05-04 07:21, Baidu (BIDU) is priced at $125,68, with a total market cap of $42,82B, a P/E ratio of 77,69, and a dividend yield of 0,00%. Today, the stock price fluctuated between $125,53 and $127,72. The current price is 0,11% above the day's low and 1,59% below the day's high, with a trading volume of 921,06K. Over the past 52 weeks, BIDU has traded between $82,39 to $165,30, and the current price is -23,96% away from the 52-week high.

BIDU Key Stats

Yesterday's Close$126,53
Market Cap$42,82B
Volume921,06K
P/E Ratio77,69
Dividend Yield (TTM)0,00%
Diluted EPS (TTM)1,70
Net Income (FY)$5,58B
Revenue (FY)$129,07B
Earnings Date2026-05-18
EPS Estimate1,68
Revenue Estimate$4,56B
Shares Outstanding338,47M
Beta (1Y)0.431

About BIDU

Baidu, Inc. provides online marketing and cloud services through an internet platform in the People's Republic of China. It operates in two segments, Baidu Core and iQIYI. The Baidu Core segment offers search-based, feed-based, and other online marketing services; cloud services; and products and other services from AI initiatives. This segment also operates Haokan, a user generated and professionally produced short videos platform. The iQIYI segment operates an online entertainment video platform that offers original, professionally produced, and partner-generated content. The company was incorporated in 2000 and is headquartered in Beijing, the People's Republic of China.
SectorCommunication Services
IndustryInternet Content & Information
CEOYanhong Li
HeadquartersBeijing,None,CN
Official Websitehttps://ir.baidu.com
Employees (FY)18,60K
Average Revenue (1Y)$6,93M
Net Income per Employee$300,48K

Baidu (BIDU) FAQ

What's the stock price of Baidu (BIDU) today?

x
Baidu (BIDU) is currently trading at $125,68, with a 24h change of -0,75%. The 52-week trading range is $82,39–$165,30.

What are the 52-week high and low prices for Baidu (BIDU)?

x

What is the price-to-earnings (P/E) ratio of Baidu (BIDU)? What does it indicate?

x

What is the market cap of Baidu (BIDU)?

x

What is the most recent quarterly earnings per share (EPS) for Baidu (BIDU)?

x

Should you buy or sell Baidu (BIDU) now?

x

What factors can affect the stock price of Baidu (BIDU)?

x

How to buy Baidu (BIDU) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

Hot Posts su Baidu (BIDU)

GateUser-bd883c58

GateUser-bd883c58

03-30 11:50
问AI · 信达生物盈利转正如何折射创新药行业新周期? **21世纪经济报道记者季媛媛** 3月26日,港股创新药龙头信达生物(01801.HK)交出了年度成绩单。财报数据显示,公司首次实现国际财务报告准则(IFRS)计量下的全年盈利,净利润达8.14亿元。同期,公司总收入突破130亿元大关,达到130.42亿元,同比增长38.4%,其中核心的产品收入达118.96亿元,同比增长44.6%。 在经历了一段时间的行业寒冬与估值重构后,这份盈利“转正”的成绩单,不仅为信达生物自身的发展注入了强心剂,更向市场传递出一个积极信号:中国头部的创新药企,正逐步跨越“投入期”,进入“收获期”。然而,在医保控费常态化、行业竞争白热化、国际化壁垒高企的多重挑战下,信达生物的突围路径,也为整个创新药行业提供了观察的范本。 有券商医药行业分析师对21世纪经济报道记者表示,在融资环境趋紧的背景下,信达通过“规模效应+精益运营”实现盈利,为持续的研发投入和BD合作腾挪出空间,避免了“有增长无质量”的困境。特别在PD-1赛道增长放缓后,信达凭借玛仕度肽在减重/代谢领域打开了新的增长曲线,有效分散了单一品种的风险,增强了业绩的稳定性和抗周期性。 “2025年,信达与武田、礼来等跨国药企达成多项重磅合作,总交易额超220亿美元。特别是与武田的‘联合开发+联合商业化’模式,标志着中国药企正从‘卖青苗’升级为‘全球合伙人’,有望分享更高的全球价值链收益。”该分析师说。 **基本盘迎变** 信达生物2025年业绩的最大亮点,在于其业务结构实现了根本性的优化。长期以来,以信迪利单抗(达伯舒®)为代表的肿瘤产品线是公司的绝对支柱。而在2025年,以减重/糖尿病药物玛仕度肽(信尔美®)、自免药物匹康奇拜单抗(信美悦®)等为代表的综合产品线,已从“蓄势”走向“爆发”,成为驱动增长的“第二引擎”。 财报显示,公司综合产品线的快速扩张,是产品收入同比增长44.6%的关键驱动力。信达生物董事会主席兼首席执行官俞德超博士在业绩会上将此概括为“肿瘤和慢病双轮驱动的发展格局”。这意味着,公司不再仅仅依赖单一治疗领域或单一重磅产品,而是构建了更为均衡、抗风险能力更强的商业化矩阵。 这一转变的商业逻辑清晰可见:肿瘤领域虽然市场空间巨大,但竞争也最为激烈,且受医保谈判影响价格压力显著。根据IQVIA发布的数据,2025年下半年肿瘤治疗免疫类药物PD-(L)1的市场患者使用占比仍然保持稳步增长。与2025年上半年相比,增长率为6.9%;与2024年下半年同比,有11.2%的增长率;环比和同比都相较25年上半年有所提高,患者使用占比保持持续上升趋势。 2025年下半年至今(截至2026年3月中旬),PD-(L)1靶点相关新获批上市产品中,瑞拉芙普α(国内商品名:艾泽利)是全球首个获批上市的PD-L1/TGF-β双特异性抗体。该药于2026年1月获国家药品监督管理局批准上市,适应症为胃及胃食管结合部腺癌的一线治疗。另外,有PD-(L)1类产品的新剂型获批上市,阿替利珠单抗(泰圣奇)皮下注射在2025年11月获批上市(注射剂上市时间为2020年2月),为首个MNC PD-L1皮下注射制剂。至此,目前共有24个PD-(L)1产品在国内获批上市。在已上市产品中,适应症/制剂扩展方面,自2025年下半年至今,已有7个产品获得新适应症批准。 如此可见,肿瘤产品市场竞争进入白热化。而慢病领域,尤其是代谢、自身免疫等,拥有庞大的患者基数、长期用药需求以及更高的市场渗透潜力。以玛仕度肽为例,作为全球首款GCG/GLP-1双受体激动剂,其9mg高剂量适应症的上市申请已获受理。在中国减重市场渗透率远低于欧美(美国GLP-1渗透率超10%,中国不足1%)的背景下,这一产品的放量空间极具想象力。 信达生物在业绩会上透露,2025年信达生物已有18款产品上市,其中12款纳入国家医保目录(NRDL),强大的商业化能力与广泛的市场覆盖,为其稳定贡献了超过百亿元的营收底盘。从首个产品上市到营收规模突破百亿元,信达仅用了约7年时间,这在国内本土药企中速度居前,也为其持续投入研发和国际化提供了“造血”能力。 **提升商业化效率** 如果说“双轮驱动”是收入端的成功,那么首次实现全年盈利,则更多体现了公司在运营效率与成本控制上的进步。2025年,信达生物Non-IFRS净利润达17.23亿元,同比增长419.6%。 首席财务官由飞在业绩会上表示,盈利的实现得益于产品快速增长带来的规模效应,以及公司持续秉持的精益经营理念。一个显著的数据是,在综合管线新产品密集上市的同时,公司的销售费用率却实现了同比下降。这表明,随着品牌认知度的提升和商业化团队的成熟,新产品的市场推广效率正在提高。 同时,公司对研发费用的管控也日益精细化。由飞指出,未来国内研发费用将保持在20-30亿人民币的区间,聚焦于现有管线的生命周期管理、早期研究以及即将上市产品的临床开发,同时充分利用中国的临床效率优势,高效推进早期临床和概念验证(PoC)。截至2025年底,信达生物手握超过35亿美元的现金储备,这笔丰厚的“家底”为其后续管线的研发推进和国际化的深度布局提供了坚实的“护城河”。 前述分析师也指出, 随着创新药加速上市,医保控费和集采将进入深水区。未来竞争的核心是商业化效率和成本控制能力。信达约80%的毛利率和优化的费用率为其应对价格压力提供了缓冲。 对于中国创新药企而言,国内市场是根基,但欧美发达国家市场才是利润和价值的“高地”。俞德超博士在业绩会上直言:“在中国医药市场,药品销售额约占全球的8%-9%,但行业利润仅约3%。要成为国际一流企业,前提是进入欧美发达市场。” 根据公开信息披露,2025年,信达生物的国际化进程从“战略储备”阶段,正式迈入“价值兑现”阶段。短短一年内,公司三项核心资产——IBI363(PD-1/IL-2α-bias)、IBI343(CLDN18.2 ADC)和IBI324已推进至或即将进入全球注册性临床研究。据合作伙伴估算,这三个产品的潜在全球市场规模合计超过600亿美元。 与此同时,公司在对外授权合作(BD)上也取得了突破性进展。与武田制药达成的全球战略合作,首付款高达12亿美元,潜在交易总额超百亿美元;与老搭档礼来的第七次合作,以及将DLL3 ADC授权给罗氏,均有力验证了其创新平台的全球竞争力。据统计,信达生物过去一年达成的合作总金额超过220亿美元,占中国创新药同期授权交易总金额的10%以上。 这些合作不仅仅是财务上的巨大收益,更关键的是,通过整合武田、礼来、罗氏等全球巨头的临床开发经验、监管沟通能力和商业化网络,信达生物正在快速学习并构建自身独立进行全球药物研发的能力。正如俞德超所期望的,未来公司将实现从“合作开发”到“独立自主开展全球药物研发”的跨越。 **打开价值天花板** 将目光从信达生物身上移开,置于整个中国创新药行业的大背景下,不难发现,信达的路径正是行业头部企业“突围”的缩影。 经历了前几年的资本狂热和泡沫期,中国创新药行业正步入一个更加理性的发展新周期。在这个周期里,单纯的“Me-too”或快速跟进策略已难以为继。企业面临着三大核心挑战:医保支付端的压力。国家医保目录谈判常态化,大幅压缩了创新药在国内市场的价格空间和利润回报周期;同质化竞争的困局。PD-1、Claudin 18.2 ADC、GLP-1等热门靶点扎堆,导致商业化竞争激烈;国际化的高门槛。欧美市场虽然利润丰厚,但监管标准严苛、临床开发成本高昂、商业化体系复杂,对企业的综合实力提出了极高要求。 面对挑战,头部药企正在探索出两条核心突围路径。一方面,深耕差异化创新,构筑技术壁垒。例如, 信达生物提出的“IO+ADC”新一代战略,以及玛仕度肽独特的GCG/GLP-1双靶点设计,都是差异化的体现。通过布局First-in-class或Best-in-class的分子,才能在激烈的市场竞争中占据定价权和品牌优势。 信达生物肿瘤管线首席研发官周辉博士在业绩会上透露,在肿瘤领域,公司还有IBI363(PD-1/IL-2)、IBI354(针对HER2低表达)以及一些全球首创的双抗分子有望推进全球临床。在代谢、免疫领域,每周一次的口服小分子、对标杜匹鲁单抗的下一代产品等,都展现了其从“跟跑”到“并跑”乃至“领跑”的雄心。 另一方面,坚定全球化战略,打开价值天花板。 这不仅是将产品卖到海外,更是要构建全球化的研发、注册、商业化能力。信达披露,已在美国组建了超百人的团队,同时通过与全球巨头的合作,汲取养分,加速成长。目标是到2030年,至少有5个分子进入全球国际多中心临床注册研究。这一目标一旦实现,将彻底打开公司的成长空间和估值体系。 然而,挑战同样不容忽视。国内方面,医保支付端的压力依然存在,例如,玛仕度肽在2026年面临同类产品降价后的市场竞争。国际方面,虽然管线推进顺利,但全球多中心临床的高昂费用、复杂的患者入组以及FDA等监管机构的审批不确定性,仍是需要跨越的障碍。 对于2026年,信达生物充满信心。公司重申了2027年实现200亿人民币收入的目标,并预计2026年仍将保持高速的收入增长。未来,信达能否将目前的“双轮驱动”优势转化为“全球一流”的终极地位,将取决于其国际化管线能否顺利开花结果,以及能否持续证明其作为全球性生物制药企业的研发和商业价值。对于整个中国创新药行业而言,信达生物的探索之路,无疑提供了一个值得持续观察和借鉴的范本。
0
0
0
0
DeepFlowTech

DeepFlowTech

04-27 02:35
作者:Bitget 一、热点要闻 美联储动态 美司法部终止美联储办公楼翻新调查 哥伦比亚特区联邦检察官办公室已正式结束对美联储办公楼项目成本超支的刑事调查,此前该项目涉及纳税人数十亿美元支出;调查终止或为特朗普提名的下任美联储主席凯文·沃什获参议院批准扫清障碍。 美联储监察长将继续内部审查,检察官表示若有需要可随时重启调查。 此举缓解了美联储内部治理不确定性,有助于稳定市场对货币政策连续性的预期,短期利好债市与风险资产定价。 国际大宗商品 伊朗提出三阶段谈判方案 中东风险溢价路径渐明 伊朗通过中间人向美方提交三阶段方案:第一阶段彻底结束战争并获得防止对伊朗及黎巴嫩再次攻击的保证;第二阶段聚焦霍尔木兹海峡管理;第三阶段才涉及核问题讨论,前两阶段未达成协议前绝不谈核。 特朗普称若伊朗想谈可直接打电话,认为战争很快结束。 摩根大通指出谈判路径已清晰,宏观焦点从地缘风险溢价转向残余“滞胀”风险,商品供给非线性风险仍存但已阶段性缓和,油价短期压力有所减轻。 宏观经济政策 DeepSeek全系列模型输入缓存价格大幅下调 DeepSeek官网宣布即日起输入缓存命中价格降至首发价的1/10,deepseek-v4-pro限时2.5折(优惠至2026年5月5日),V4-Pro输入(缓存命中)成本降至0.025元/百万Tokens。 高盛认为V4通过混合注意力架构创新大幅压缩长上下文成本,押注华为昇腾950量产后API定价将进一步下降,国内AI竞争将转向编程与多模态差异化。 此举强化中国AI模型成本竞争力,加速智能体应用落地,利好云计算与数据中心板块长期需求。 二、市场复盘 大宗商品&外汇表现 现货黄金:4,677美元/盎司附近,24H下跌约0.62%,受油价波动及谈判进展影响,短期滞胀担忧仍支撑金价但上行动能暂缓。 现货白银:75美元/盎司附近,24H下跌约0.96%,工业需求担忧叠加贵金属整体回调。 WTI原油:96.20美元/桶,24H上涨约1.91%,伊朗谈判路径清晰缓解供给中断担忧但地缘余波仍存。 布伦特原油:107美元/桶附近,24H涨约2%,霍尔木兹海峡管理成为第二阶段焦点。 美元指数:受美联储调查结束及谈判进展提振,小幅走强至98.61,压制非美资产表现。 加密货币表现 BTC:约78,623美元,24H上涨约1.43%,连续两日小幅反弹。 ETH:约2,367美元,24H上涨约2.21%,跟随大盘反弹。 加密货币总市值:约2.7万亿美元,24H上涨约1.3%,风险偏好回暖带动整体回升。 市场爆仓情况:24H总爆仓约1.53亿美元,空单爆仓约1.19亿美元。 Bitget BTC/USDT清算地图:当前价格约在 78,600,一旦上破 79k 上方密集空头清算区,容易触发连锁“挤空”推动价格进一步上行。但下方 77k–78k 仍有较多多头杠杆堆积,若回落则可能快速触发多头清算,形成剧烈双向波动。 美股指数表现 道指:49,230.71点,下跌0.16%,连续走势偏弱,能源敏感板块受油价影响拖累。 标普500:7,165.08点,上涨0.80%,再创历史新高,科技权重股贡献突出。 纳指:24,836.60点,上涨1.63%,连续多日新高,AI与半导体板块驱动明显。 科技巨头动态 截至上周五收盘: 英伟达 (NVDA):上涨4.32%,价格创新高,市值突破5万亿美元,AI资本支出预期持续推升。 亚马逊 (AMZN):上涨3.49%,云业务与AI基础设施需求强劲。 微软 (MSFT):上涨2.13%,Azure云增长与OpenAI合作预期支撑。 Meta (META):上涨2.41%,广告业务与AI应用落地加速。 谷歌 (GOOGL):上涨1.63%,拟最高投资400亿美元加深与Anthropic合作。 苹果 (AAPL):下跌0.87%,新CEO任命消息未完全抵消增长担忧。 特斯拉 (TSLA):小幅波动,自动驾驶与能源业务关注度提升。 整体科技七巨头多数上涨,核心驱动为AI资本支出验证临近与地缘风险缓和。 板块异动观察 半导体板块涨超3% 代表个股:英伟达 (NVDA) 涨4.32%、AMD (AMD) 大涨14% 驱动因素:AI算力与数据中心资本开支预期持续高位,英特尔财报大幅超预期并上调Q2指引,引发整个半导体产业链信心共振。AMD作为数据中心CPU关键玩家,直接受益于行业乐观情绪外溢。Burry虽警告半导体估值已进入超买区间,但当前市场资金风险偏好提升,技术面多头排列仍较为完整。本周科技巨头财报季将成为检验AI实际支出落地的重要验证期。 中概股板块上涨2.62% 代表个股:百度 (BIDU) 涨超5%、小鹏汽车 (XPEV) 涨超4% 驱动因素:伊朗提出明确三阶段谈判方案,地缘风险溢价显著回落,全球风险偏好明显回暖;叠加DeepSeek大幅降低AI模型输入缓存价格,强化了中国AI技术的成本竞争力。百度作为AI大模型与搜索龙头,受益于国内智能体应用加速预期;小鹏汽车则在智能驾驶技术与海外市场布局上展现韧性。中概科技资产出现内外利好共振下的估值修复行情。 三、深度个股解读 1. 英伟达 (NVDA) - 市值重返5万亿美元大关 事件概述:4月24日(上周五)英伟达股价上涨4.3%,收于208.27美元,市值成功突破5万亿美元,再度成为全球最有价值上市公司。今年以来累计涨幅已超过12%。作为AI算力核心供应商,公司持续受益于 hyperscalers 大规模资本开支。本周微软、亚马逊、谷歌、Meta将密集发布财报,其AI基础设施和资本支出指引将成为市场判断英伟达中期需求的关键催化剂。 市场解读:多家机构认为,尽管短期估值处于高位且技术面出现超买信号,但英伟达在AI芯片领域的绝对主导地位短期难以撼动。基本面由数据中心强劲需求驱动,Blackwell架构出货节奏良好。分析师普遍上调全年收入预期,强调其在AI训练和推理市场的护城河优势。 投资启示:AI资本开支验证窗口即将开启,建议投资者在财报季波动中寻找分批布局机会,重点关注大厂资本支出实际执行情况。 2. 谷歌 (GOOGL) - 最高追加400亿美元投资Anthropic 事件概述:谷歌母公司Alphabet宣布计划最高向AI初创公司Anthropic投资400亿美元,其中首期10亿美元已确认投入,后续300亿美元将根据Anthropic达成特定性能里程碑后分阶段注入。本次投资估值约3500-3800亿美元,主要用于支持Anthropic大规模扩展计算基础设施。Anthropic近期推出的Claude Code编程代理产品取得重大突破,进一步加速其商业化进程。 市场解读:机构普遍看好谷歌通过深化与Anthropic的战略合作,在激烈AI竞赛中形成多模型布局优势,同时巩固其在搜索、云服务及企业AI解决方案领域的竞争力。高盛等投行维持谷歌云计算板块首选推荐,认为此举有助于对抗微软-OpenAI联盟。 投资启示:AI生态深度绑定将为谷歌长期增长提供新动能,建议持续跟踪Anthropic里程碑达成情况及后续资本支出落地节奏。 3. 太空军“金穹”计划 - 12家公司获32亿美元合同 事件概述:美国太空军Space Force于4月24日宣布,向包括SpaceX、诺斯罗普·格鲁曼、洛克希德·马丁、安杜里尔等在内的12家公司授予总价值最高32亿美元的20项合同,用于开发天基导弹拦截系统原型。这是特朗普政府“金穹”导弹防御计划的重要组成部分,目标在2028年前展示具备实战能力的综合作战系统。该计划旨在构建多层导弹防御网络,有效应对弹道导弹、高超音速导弹及无人机威胁。 市场解读:国防航天板块获得实质性大额订单提振,机构认为在地缘政治风险尚未完全消除的背景下,“金穹”计划推进将为相关国防承包商带来长期稳定收入来源。SpaceX等新兴公司参与也反映出五角大楼加速采用商业创新技术的趋势。 投资启示:尽管中东谈判路径逐渐清晰,国防科技板块仍具备较强防御属性,适合作为组合对冲配置,重点关注合同后续执行进展和相关公司季度订单增长情况。 四、加密货币项目动态 1、一位巨鲸在两年未活跃后,将 300 个比特币(价值 2340 万美元)存入币安。这 300 个比特币是三年前从 Bitfinex 交易所提取的,当时比特币价格为 19329 美元。如今,这位巨鲸坐拥 1760 万美元的利润。 2、Strategy 创始人 Michael Saylor 昨日再次发布比特币 Tracker 相关信息,配文:“The ₿eat Goes On.。”根据此前规律,Strategy 总是在相关消息发布之后的第二天披露增持比特币信息。 3、数据:SUI、JUP、SIGN等代币本周将迎来大额解锁,其中SUI解锁价值约4000万美元。 4、VanEck 分析师 Matthew Sigel 和 Patrick Bush 撰文分析称,比特币出现了两个历史上看涨的信号:负资金费率和哈希率集中下降,同时波动性有所降温。随着美伊紧张局势的缓和,比特币的实现波动率从 56% 降至 41%,同时 7 天平均资金费率转为负值至 -1.8%,创下 2023 年以来的最低水平。从历史数据来看,负资金费率通常预示着强劲的未来收益:自 2020 年以来,负资金费率期间的 30 天比特币平均收益率为 +11.5%,而整体收益率为 +4.5%,命中率高达 77%。低于 -5% 的资金费率在 30 天周期内带来了 +19.4% 的收益。此外,算力在过去 30 天内已降至第 16 个百分点,这是自 2021 年禁止挖矿以来,算力回落最为集中的一次。在过去 7 次算力回落中,有 6 次在 90 天后比特币价格上涨,中位数涨幅为 +37.7%。 5、萨尔瓦多过去 7 日共增持 8 枚比特币,过去 30 天增持 31 枚,目前其比特币持仓达 7,633.37 枚,总价值达 6.24 亿美元。 6、链上分析平台 Arkham 在 X 平台发布监测数据显示,以太坊基金会已解质押价值约4890万美元的ETH。链上操作显示,以太坊基金会已将其持有的 WSTETH 存入 Lido 的 unstETH 解质押合约,待解锁流程完成后,将获得对应数量的 ETH 现货。 当前加密市场核心聚焦该笔资产的后续动向,高度关注以太坊基金会是否会将解锁后的 ETH 进行抛售。此前,以太坊基金会曾多次抛售 ETH 用于运营资金管理,相关操作均引发市场对 ETH 潜在抛压的持续担忧。 五、今日市场日历 数据发布时刻表 重要事件预告 科技巨头财报:4月30日凌晨(UTC+8)谷歌、微软、Meta、亚马逊同日发布,市场重点关注AI资本支出与云收入增速。 美联储相关:凯文·沃什提名进展或有新消息,关注参议院表态。 机构观点: 摩根大通全球市场策略团队表示,虽然中东局势尚未完全解决,但谈判路径已显著清晰,宏观焦点正从地缘风险溢价转向残余“滞胀”压力。在这一框架下,股票市场分化将进一步加剧:资金更倾向于对经济敏感度较低、却能持续兑现增长的结构性赛道,尤其是AI与“安全/韧性”相关投资;商品与纯周期板块权重则可能被调降。高盛同样看好DeepSeek等AI模型的成本优势,认为其将加速智能体应用落地并带动云计算需求。整体而言,机构维持对科技与AI链条的超配观点,同时建议关注本周科技巨头财报对资本开支的验证结果。地缘风险缓和叠加ETF资金流入,为加密市场提供了阶段性支撑,但滞胀余波仍需警惕。 免责声明:以上内容由AI搜索整理,人工仅作验证发布,不作为任何投资建议。
0
0
0
0
SelfRugger

SelfRugger

04-19 10:06
As Tesla Gains U.S. Market Share, Should You Buy TSLA Stock? ============================================================ AI microchip by DesignKingBD360 via Shutterstock Aditya Raghunath Wed, February 18, 2026 at 6:21 AM GMT+9 5 min read In this article: TSLA -1.63% When a company tells you it's not what you think it is anymore, you should probably listen. That's the message Tesla (TSLA) delivered to investors during its fourth-quarter earnings call last month. The Austin-based electric vehicle (EV) maker is making a sharp pivot away from cars and toward artificial intelligence, robotics, and autonomous vehicles. ### More News from Barchart * Calm Waters for Alphabet (GOOG, GOOGL) Stock Present a Tempting Options Trade * Amazon Put Options at Lower Strike Prices Have High Yields * Is GOOG Stock a Buy Amid the Software Selloff? * Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! The timing seems odd. Tesla just reported its first-ever annual revenue decline, and vehicle deliveries dropped 8.6% in 2025. Yet CEO Elon Musk is doubling down on a vision that has some analysts calling it a "burn the ships" moment and others warning of serious risks ahead. For investors trying to decide whether to buy Tesla stock, the question isn't really about EVs anymore. It's about whether you believe Musk can pull off one of the most ambitious business transformations in corporate history. www.barchart.com Tesla's Market Share Remains Under Pressure ------------------------------------------- Here's the paradox: Tesla's U.S. sales fell 17% in January, according to state registration data. But the EV giant may have gained market share. Total EV sales in the U.S. dropped over 20% during the same period, according to estimates. When the entire market shrinks faster than your sales, you can lose volume but gain share. Looking at the bigger picture, Tesla delivered about 1.64 million vehicles in 2025. That's down from 1.79 million in 2024, which was already down from the 2023 total of 1.81 million. The company's years of rapid expansion seem to be over. After growing 38% year-over-year (YOY) in 2023, deliveries essentially flatlined in 2024 before contracting in 2025. Softer global demand, increased competition (especially from China's BYD), and internal model changes all contributed to the decline. Tesla Is Pivoting to AI and Robotics ------------------------------------ During the earnings call, Musk announced that Tesla will stop producing the Model S sedan and Model X SUV next quarter. These vehicles helped make electric cars mainstream when they launched in 2012 and 2015, but they now represent less than 3% of Tesla's delivery volume. The production lines at the Fremont, California, factory will be converted to manufacture Optimus humanoid robots instead. Musk's goal is ambitious: one million Optimus units per year from that facility alone. Story Continues * Capital expenditures will more than double this year to over $20 billion, up from $8.6 billion in 2025. * Tesla CFO Vaibhav Taneja said the money will fund six new factories, including facilities for battery storage, the driverless Cybercab, semi-electric trucks, and the Optimus robot factory. * Additional spending will go toward AI computing infrastructure and expanding existing factories. Musk acknowledged that Optimus is still in research and development mode. "We're still very much at the early stages," he said on the call. Notably, Tesla doesn't expect significant production volume until the end of 2026. In 2024, Musk suggested that Optimus could eventually make Tesla a $25 trillion company. The current market cap sits at $1.57 trillion. He's also claimed that 80% of Tesla's value will eventually come from robots. Tesla’s Autonomous Driving Bet ------------------------------ Further, Tesla is expanding its Robotaxi ride-hailing fleet across the U.S. The company launched a pilot service in Austin, Texas, in 2025 and recently began testing driverless passenger rides without human safety supervisors. According to the company's investor presentation, Tesla plans to expand coverage to seven additional markets in the first half of 2026: Dallas, Houston, Phoenix, Miami, Orlando, Tampa, and Las Vegas. Additionally, Tesla is building the Cybercab, a two-seat driverless vehicle with no steering wheel or pedals. Production is scheduled to start in April, though Musk has a history of missing self-imposed deadlines. Competition in autonomous vehicles is intense. Alphabet's (GOOG) (GOOGL) Waymo is rapidly expanding in the U.S., while Baidu's (BIDU) Apollo Go is growing in China. Tesla’s Top Line Growth Decelerates ----------------------------------- Tesla's fourth-quarter results beat analyst expectations, with adjusted earnings per share of $0.40 versus estimates of $0.45. Revenue came in at $24.90 billion compared to estimates of $24.79 billion. But for the full year, revenue fell 3% to $94.8 billion from $97.7 billion in 2024. This marked the first annual revenue decline in company history. Automotive revenue, which still accounts for about 70% of Tesla's business, dropped 10% in 2025. The company faced stiff competition from BYD (BYDDF) in China and from Volkswagen (VWAGY) and BMW (BMWKY) in Europe. Net income in the fourth quarter plunged 61% to $840 million as operating expenses jumped 39%. Tesla said the cost increase was driven by AI and other research and development projects. Also, Tesla announced it would invest about $2 billion in Musk's AI startup xAI. The company said the investment is "intended to enhance Tesla's ability to develop and deploy AI products and services into the physical world at scale." Tesla's brand value declined by $15.4 billion in 2025, a 36% drop, according to Brand Finance. The firm cited a lack of innovative new EV models, relatively high prices compared to competitors, and Musk's controversial political activities. Consumer recommendation scores in the U.S. fell to 4.0 out of 10, down from 8.2 in 2023, which basically means people aren't willing to recommend a Tesla to friends and family. The Bottom Line for TSLA Stock Investors ---------------------------------------- www.barchart.com www.barchart.com Out of the 42 analysts covering Tesla stock, 14 recommend “Strong Buy”, two recommend “Moderate Buy”, 17 recommend “Hold”, and nine recommend “Strong Sell”. The average TSLA stock price target is $406.94, below the current price of $410.85. If you believe Tesla can successfully scale autonomous vehicles, humanoid robots, and AI chips while managing the enormous capital requirements and technical challenges, then the current TSLA stock price might look attractive. However, if you think the EV heavyweight is abandoning a profitable car business for unproven technologies with intense competition and uncertain timelines, you'll want to stay away. One thing is clear: Tesla is no longer primarily an EV company. For better or worse, it's betting its future on AI and robotics. Investors need to be comfortable with that reality before buying the stock. _ On the date of publication, Aditya Raghunath did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com _ Terms and Privacy Policy Privacy Dashboard More Info
0
0
0
0